2020
Ophthalmic Medication Expenditures and Out-of-Pocket Spending An Analysis of United States Prescriptions from 2007 through 2016
Chen EM, Kombo N, Teng CC, Mruthyunjaya P, Nwanyanwu K, Parikh R. Ophthalmic Medication Expenditures and Out-of-Pocket Spending An Analysis of United States Prescriptions from 2007 through 2016. Ophthalmology 2020, 127: 1292-1302. PMID: 32359935, PMCID: PMC7508869, DOI: 10.1016/j.ophtha.2020.04.037.Peer-Reviewed Original ResearchConceptsOphthalmic medicationsMedication expendituresOOP expenditureLongitudinal cohort studyOverall drug expendituresUnited States populationPrescription drug spendingGlaucoma medicationsCohort studyMedication useDry eyePrescription usePrescription expendituresPrescription medicationsOOP expensesMedicationsCopayment assistancePocket expenditureOOP spendingDrug expendituresPocket spendingDrug spendingIndirect costsMEPS participantsLinear regression
2015
A Therapeutic Trial of Valganciclovir in Patients with Uveitis and Positive Epstein-Barr virus Early Antigen D IgG Titers
Boonsopon S, Maghsoudlou A, Kombo NE, Foster CS. A Therapeutic Trial of Valganciclovir in Patients with Uveitis and Positive Epstein-Barr virus Early Antigen D IgG Titers. European Journal Of Ophthalmology 2015, 26: 30-35. PMID: 26350994, DOI: 10.5301/ejo.5000673.Peer-Reviewed Original ResearchConceptsPositive Epstein-Barr virusEpstein-Barr virusTherapeutic trialsEBV infection/reactivationInfection/reactivationMassachusetts Eye ResearchCauses of uveitisRetrospective chart reviewImmunoglobulin G titersSurgery institutionsValganciclovir therapyEBV reactivationImmunomodulatory therapyIntraocular inflammationChart reviewIgG titersPersistent inflammationEA antibodyEBV-EAG titersValganciclovirNegative studiesUveitisPatientsInflammation